The Israeli Health Ministry has launched an extensive set of recommendations to revamp the medical cannabis system in Israel. This comes after a professional committee, led by Dr. Gilad Bodenheimer, reviewed the current practices associated with cannabis prescriptions.
The proposed changes cover everything from the conditions that justify cannabis use to how it should be dosed, monitored, and discontinued. The ministry emphasizes that while cannabis can aid some patients, it also poses risks requiring careful medical management rather than free-market availability.
Over the last decade, the use of medical cannabis in Israel has soared. Annual licenses skyrocketed from 33,000 to about 140,000, making Israel one of the highest consumers of medical cannabis worldwide.
The increase in use is partly attributed to rising numbers of individuals seeking relief from pain and psychological distress, especially since recent conflicts. However, there’s a call for rigorous control to ensure patient safety and effective treatment.
Recent data reveals that about 62% of patients consume over 30 grams per month. Alarmingly, 88% of licenses allow for high THC concentrations, and smoking remains the most common method of consumption—accounting for up to 98% of sales. This raises concerns about health risks and dosing accuracy.
One major recommendation is to phase out smoking cannabis completely within three years, as experts argue it poses health risks and leads to inconsistent dosing. New patients would primarily use cannabis extracts or inhalers, with strict supervision for any exceptions.
The committee also suggests starting patients on lower doses, favoring a balance of THC to cannabidiol (CBD), especially for vulnerable groups like the elderly or terminally ill.
A significant shift proposed would put the responsibility for prescribing, monitoring, and dispensing cannabis under the health maintenance organizations (HMOs). This would unify cannabis treatment with broader healthcare records, enhancing care continuity.
Caution is also advised concerning cannabis use for post-traumatic stress disorder (PTSD). Although the committee doesn’t recommend removing this indication, it cautions that research on long-term benefits remains inconclusive and questions the potential for functional impairment.
Physicians would be required to assess addiction risks before treating patients with cannabis. They’d need to watch for warning signs such as escalating doses and frequent doctor shopping. Renewals of prescriptions would require regular evaluations after six months.
Experts agree that while medical cannabis has demonstrated benefits for some conditions, it must be approached with caution. Investing in clinical research to explore safer consumption methods, such as vaporization, is a crucial next step.
Overall, the Israeli Health Ministry aims to balance accessibility and patient safety in the evolving medical cannabis landscape. All medical treatments, they assert, must carefully weigh the benefits against potential harms. This emphasis on responsible prescribing could lead to a more secure and effective system for patients in need.
Source link
elderly,Health Ministry,PTSD,Cannabis,Medical cannabis
